Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502986 | 1.00 | NAAA (0.39) | NAAAALOX5EPHX1CYP1A2ALDH1A1 | |
| SCHEMBL29206937 | 1.00 | NAAA (0.39) | NAAAALOX5EPHX1CYP1A2ALDH1A1 | |
| SCHEMBL191084 | 1.00 | NAAA (0.39) | NAAAALOX5EPHX1CYP1A2ALDH1A1 | |
| SCHEMBL31231268 | 0.95 | NAAA (0.36) | NAAAALOX5EPHX1 | |
| SCHEMBL2519349 | 0.86 | NAAA (0.47) | NAAAALOX5EPHX1CYP1A2ALDH1A1 | |
| SCHEMBL23610185 | 0.85 | ALOX5 (0.50) | NAAAALOX5EPHX1CYP1A2ALDH1A1 | |
| SCHEMBL6865203 | 0.84 | PTGER2 (0.37) | — | |
| SCHEMBL10883546 | 0.82 | ALOX5 (0.39) | NAAAALOX5EPHX1CYP1A2SIGMAR1 | |
| SCHEMBL6430891 | 0.82 | ALOX5 (0.39) | NAAAALOX5EPHX1CYP1A2SIGMAR1 | |
| SCHEMBL14074014 | 0.81 | ALOX5 (0.39) | NAAAALOX5EPHX1CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |